Literature DB >> 21871053

Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.

Alessandro Zucchi1, Giacomo Novara, Elisabetta Costantini, Alessandro Antonelli, Marco Carini, Giorgio Carmignani, Sergio Cosciani Cunico, Dario Fontana, Nicola Longo, Guido Martignoni, Andrea Minervini, Vincenzo Mirone, Massimo Porena, Marco Roscigno, Riccardo Schiavina, Claudio Simeone, Alchiede Simonato, Salvatore Siracusano, Carlo Terrone, Vincenzo Ficarra.   

Abstract

OBJECTIVES: To investigate cancer-related outcomes and prognostic factors of papillary renal cell carcinoma (pRCC) in a large multicentre data set. Oncological outcome and prognostic factors of pRCC have been limitedly evaluated in comparison with the most common RCC subtype, clear cell RCC. PATIENTS AND METHODS: From a multicentre retrospective database, including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007, 577 patients with pRCC were identified. Univariable and multivariable Cox regression models were performed to identify prognostic factors predictive of recurrence-free survival (RFS) and cancer-specific survival (CSS) after surgery.
RESULTS: At a median (interquartile range) follow-up of 39.2 (21.7-72) months, 81 (14%) patients had experienced disease progression and 63 (11%) patients had died from disease; the 5-year RFS estimate was 85.5%. In multivariable analysis, pathological N stage (pooled P < 0.001), M stage (hazard ratio, 2.9; P= 0.007) and Fuhrman nuclear grade (pooled P= 0.039) were all independent predictors of RFS; the 5-year CSS estimate was 87.9%. In Cox multivariable analysis, an independent predictive role was reconfirmed for mode of presentation (pooled P= 0.038), pathological N stage (pooled P < 0.001), M stage (hazard ratio, 2.4; P= 0.049) and Fuhrman nuclear grade (pooled P= 0.037).
CONCLUSIONS: Patients with pRCC have a low risk of tumour recurrence and cancer-related death after surgery. Fuhrman nuclear grade was found to be a stronger predictor of both RFS and CSS, whereas only a non-statistically significant trend was found for the 2009 pathological T stage.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2011        PMID: 21871053     DOI: 10.1111/j.1464-410X.2011.10517.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

Review 1.  Correlating Preoperative Imaging with Histologic Subtypes of Renal Cell Carcinoma and Common Mimickers.

Authors:  Jennifer Gordetsky; Jessica Zarzour
Journal:  Curr Urol Rep       Date:  2016-07       Impact factor: 3.092

2.  Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.

Authors:  Alcides Chaux; Luciana Schultz; Roula Albadine; Jessica Hicks; Jenny J Kim; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Hum Pathol       Date:  2012-04-26       Impact factor: 3.466

3.  Prognostic factors for the survival of patients with papillary renal cell carcinoma after surgical management.

Authors:  W Ren; X Gao; X Zhang; J Hu; H Li; X Zu
Journal:  Clin Transl Oncol       Date:  2019-07-17       Impact factor: 3.405

4.  Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.

Authors:  Kunpeng Liu; Yuan Ren; Lijuan Pang; Yan Qi; Wei Jia; Lin Tao; Zhengyan Hu; Jin Zhao; Haijun Zhang; Li Li; Haifeng Yue; Juan Han; Weihua Liang; Jianming Hu; Hong Zou; Xianglin Yuan; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

5.  Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery.

Authors:  Rodrigo A Ledezma; Edris Negron; Gladell P Paner; Chris Rjepaj; Danny Lascano; Mohammed Haseebuddin; Pankaj Dangle; Arieh L Shalhav; Henry Crist; Jay D Raman; G Joel DeCastro; Lara Harik; Monika Paroder; Robert G Uzzo; Alexander Kutikov; Scott E Eggener
Journal:  World J Urol       Date:  2015-09-25       Impact factor: 4.226

6.  Clinico-pathological analysis of renal cell carcinoma demonstrates decreasing tumour grade over a 17-year period.

Authors:  Gregory J Nason; Barry B McGuire; Michael E Kelly; Theodore M Murphy; Aisling T Looney; Damien P Byrne; David W Mulvin; David J Galvin; David M Quinlan; Gerald M Lennon
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

7.  The effect of the papillary renal cell carcinoma subtype on oncological outcomes.

Authors:  Honghong Pan; Liefu Ye; Qingguo Zhu; Zesong Yang; Minxiong Hu
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

8.  Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Shengwei Xiong; Weijie Zhu; Xinfei Li; Yanfei Yu; Kunlin Yang; Lei Zhang; Yue Mi; Xuesong Li; Liqun Zhou
Journal:  Transl Androl Urol       Date:  2021-08

9.  Prognostic Effect of Subclassification on Oncological Outcomes in Patients with Surgically Treated Localized Papillary Renal Cell Carcinoma: A Retrospective Propensity Score-matched Cohort Study.

Authors:  Shijie Li; Xuefeng Liu; Xiaonan Chen
Journal:  J Cancer       Date:  2022-01-16       Impact factor: 4.207

Review 10.  Metachronous bladder metastases of a type 2 papillary renal cell carcinoma: a case report and review of the literature.

Authors:  D G V D Seneth Gajasinghe; Ishra Nazeer; Hansika P Maddumage; Chrysantha Perera; Anuruddha M Abeygunasekera
Journal:  World J Surg Oncol       Date:  2016-08-22       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.